Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.64 |
| ▸ | SRC | P12931 | 7/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.64 |
| ▸ | FLT4 | P35916 | 3/20 | 0.64 |
| ▸ | TEK | Q02763 | 3/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.64 |
| ▸ | RET | P07949 | 2/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | GAK | O14976 | 1/20 | 0.64 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.64 |
| ▸ | ERN1 | O75460 | 1/20 | 0.64 |
| ▸ | STK10 | O94804 | 1/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382463 | 0.96 | KDR (0.58) | KDRSRCPDGFRBFLT4TEK | |
| SCHEMBL4375632 | 0.94 | KDR (0.57) | KDRSRCPDGFRBFLT4TEK | |
| SCHEMBL4376403 | 0.94 | SRC (0.61) | KDRSRCPDGFRBFLT4TEK | |
| SCHEMBL2953331 | 0.93 | KDR (0.73) | KDRSRCPDGFRBFLT4TEK | |
| SCHEMBL4375084 | 0.92 | KDR (0.65) | KDRSRCPDGFRBFLT4TEK | |
| SCHEMBL4378613 | 0.92 | ABCB11 (0.74) | KDRSRCPDGFRBFLT4TEK | |
| SCHEMBL1401650 | 0.91 | KDR (0.67) | KDRSRCPDGFRBFLT4TEK | |
| SCHEMBL15966438 | 0.91 | KDR (0.76) | KDRSRCPDGFRBFLT4TEK | |
| SCHEMBL4379499 | 0.89 | EGFR (0.51) | KDRSRCPDGFRBFLT4TEK | |
| SCHEMBL15966441 | 0.89 | KDR (0.65) | KDRSRCPDGFRBFLT4TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | claimed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | claimed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | claimed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | claimed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | claimed |
| US-11369611-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3763710-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | Kala Pharmaceuticals, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200323854-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2020-10-15 | — | — | US | disclosed |
| US-10758539-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190216812-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2019-07-18 | — | — | US | disclosed |
| US-10285991-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180104246-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2018-04-19 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10285991-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | KDR 4398/4885SRC 4354/4885PDGFRB 3074/4885 |
| US-10758539-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | KDR 4398/4885SRC 4354/4885PDGFRB 3074/4885 |
| US-11369611-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | KDR 4398/4885SRC 4354/4885PDGFRB 3074/4885 |
| US-20190216812-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | KDR 4398/4885SRC 4354/4885PDGFRB 3074/4885 |
| US-20200323854-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | KDR 4398/4885SRC 4354/4885PDGFRB 3074/4885 |
| US-20180104246-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | KDR 4398/4885SRC 4354/4885PDGFRB 3074/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | KDR 4/4885SRC 1276/4885PDGFRB 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.